Leiv Askvig

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers. Oncoinvent – Innovations for better cancer care.

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 650 patients at 100 clinics in 15 countries, in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is privately held, mainly by Norwegian private investors/family offices. Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.

Om Civita: Civita er en liberal tankesmie med et ideelt mål. Civita skal formidle kunnskap og ideer som er tankevekkende og utvider rommet for den politiske debatt, og fremme forslag til reformer. Civita vil vektlegge det idébaserte og prinsipielle perspektivet i samfunnsdebatten. Civita skal fremme, ikke bare forklare, betydningen av liberale verdier, blant annet gjennom utredning og analyse, deltakelse i samfunnsdebatten, skolering, møter og publikasjoner. Blant de mest sentrale liberale verdiene og ideene er det liberale demokratiet, menneskerettighetene, en fri og åpen økonomi, et sterkt sivilt samfunn og det personlige ansvar. Liberale rettigheter beskytter og muliggjør individets frihet. Civita skal fungere som et nettverk av personer med ulik politisk partitilhørighet, og fra ulike deler av samfunnet (akademia, næringsliv, media, organisasjonsliv og politikk). Civita skal opptre uavhengig av politiske partier, interesseorganisasjoner og offentlige myndigheter. Formål: Civita arbeider for økt kunnskap og oppslutning om liberale verdier, institusjoner og løsninger, for å fremme en samfunnsutvikling basert på respekt for individets frihet og personlige ansvar. Civita skal realisere sitt formål gjennom utredninger og analyser, deltakelse i samfunnsdebatten, skolering, møter og seminarer. Realiseringen av Civitas formål er betinget av økonomisk støtte fra et mangfold av private bidragsytere.

Astrup Fearnley, through its subsidiaries, is a leading provider of shipping, offshore, energy, real estate and financial advisory, research and brokerage services worldwide. The Astrup Fearnley Group traces back to 1869 and have a strong global presence with 14 offices in 10 countries employing 350 professionals. Read more about our subsidiaries; www.fearnleys.com www.fearnleyoffshore.com www.fearnleysecurities.com www.fearnleyoffshoresupply.com And don't forget to visit the Astrup Fearnley Museum at www.afmuseet.no

Pandox is a leading owner of hotel properties in Northern Europe with a focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 157 hotels with approximately 35,500 hotel rooms in 15 countries. Pandox’s business is organised into Property management, which comprises hotel properties leased on a long-term basis to market leading hotel operators, and Operator activities, which comprises hotel operations executed by Pandox in its owner-occupied hotel properties. Pandox was founded in 1995 and the company’s B shares are listed on Nasdaq Stockholm. www.pandox.se

Oncoinvent is a clinical stage company committed to developing new innovative radiopharmaceutical products for better treatment options for cancer patients. Radspherin®, the company’s lead product candidate is a novel alpha-emitting radioactive microsphere suspension designed for treatment of metastatic cancers in body cavities. Radspherin® has shown strong and consistent anticancer activity at essentially non-toxic doses in preclinical studies and is anticipated to potentially treat several forms of metastatic cancer. Situated in Oslo, Oncoinvent’s main offices include modern laboratory facilities suitable for cGMP and radiopharmaceutical manufacture for clinical trials and research. The development programs of the company include radiotherapeutic and radioimmunotherapeutic products with focus on alpha-emitting radionuclides for treatment of various solid cancers. Oncoinvent – Innovations for better cancer care.

We have managed highly active, value-based equity and fixed income funds on behalf of clients for over 30 years. SKAGEN is part of Storebrand Asset Management but operates as an independent boutique with its own Board. Our funds are administered by Storebrand but managed by SKAGENs investment team. We are stock pickers who do all our own company research and analysis. We think long-term and are unafraid to invest in unpopular companies if it is in the best interests of the funds unitholders – when they do well, we do well. Our objective is to provide the best possible risk-adjusted returns. - - - This is marketing communication. Historical returns are no guarantee for future returns. There is risk associated with investing in funds. Before subscribing, you are encouraged to read the funds key information and prospectus.

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. Ultimovacs is performing a broad clinical development program with clinical trials in Europe, Australia, and the USA; Five Phase II trials enrolling more than 650 patients at 100 clinics in 15 countries, in melanoma, mesothelioma, head & neck cancer, ovarian cancer, and non-small cell lung cancer. Ultimovacs was established in 2011. The company and its proprietary technology is based on pre-clinical and clinical research on immunotherapies conducted at the Oslo University Hospital. The company is privately held, mainly by Norwegian private investors/family offices. Ultimovacs is headquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway, and also has an office in Uppsala, Sweden. Ultimovacs is an active member of Oslo Cancer Cluster.

Om Civita: Civita er en liberal tankesmie med et ideelt mål. Civita skal formidle kunnskap og ideer som er tankevekkende og utvider rommet for den politiske debatt, og fremme forslag til reformer. Civita vil vektlegge det idébaserte og prinsipielle perspektivet i samfunnsdebatten. Civita skal fremme, ikke bare forklare, betydningen av liberale verdier, blant annet gjennom utredning og analyse, deltakelse i samfunnsdebatten, skolering, møter og publikasjoner. Blant de mest sentrale liberale verdiene og ideene er det liberale demokratiet, menneskerettighetene, en fri og åpen økonomi, et sterkt sivilt samfunn og det personlige ansvar. Liberale rettigheter beskytter og muliggjør individets frihet. Civita skal fungere som et nettverk av personer med ulik politisk partitilhørighet, og fra ulike deler av samfunnet (akademia, næringsliv, media, organisasjonsliv og politikk). Civita skal opptre uavhengig av politiske partier, interesseorganisasjoner og offentlige myndigheter. Formål: Civita arbeider for økt kunnskap og oppslutning om liberale verdier, institusjoner og løsninger, for å fremme en samfunnsutvikling basert på respekt for individets frihet og personlige ansvar. Civita skal realisere sitt formål gjennom utredninger og analyser, deltakelse i samfunnsdebatten, skolering, møter og seminarer. Realiseringen av Civitas formål er betinget av økonomisk støtte fra et mangfold av private bidragsytere.

Astrup Fearnley, through its subsidiaries, is a leading provider of shipping, offshore, energy, real estate and financial advisory, research and brokerage services worldwide. The Astrup Fearnley Group traces back to 1869 and have a strong global presence with 14 offices in 10 countries employing 350 professionals. Read more about our subsidiaries; www.fearnleys.com www.fearnleyoffshore.com www.fearnleysecurities.com www.fearnleyoffshoresupply.com And don't forget to visit the Astrup Fearnley Museum at www.afmuseet.no